Google's services have been blocked in China for several years, but the company still has businesses there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
The House voted to table a resolution to start impeachment proceedings against President Donald Trump introduced by Rep. Al Green.Politicsread more
Investors will be watching out for the release of Australian jobs data, set to be at 9:30 a.m. HK/SIN.Asia Marketsread more
The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
See which stocks are posting big moves after the bell on July 17.Market Insiderread more
"It's clearly doing more harm than good," the "Mad Money" host says. Instead Facebook should buy Square for $70 billion and expand the payments network worldwide.Mad Money with Jim Cramerread more
Silicon Valley workers say they gravitate toward Yang, who is running for president as a Democrat, because of his approach to research and understanding of tech's moral...Technologyread more
Prosecutors in Masschusetts have dropped a criminal case against actor Kevin Spacey, who had been accused of groping an 18-year-old man.Entertainmentread more
"The passport contains numerous ingress and egress stamps, including stamps that reflect use of the passport to enter France, Spain, the United Kingdom, and Saudi Arabia in...Politicsread more
Pharmaceutical companies aren't often associated with technology prowess, but a select few are trying to change that.
The goal is to hire engineers to help modernize the processes that big pharma uses to discover and develop new drugs.
GSK alone has more than a dozen former employees from the largest tech companies working under its chief data officer Mark Ramsey, who was himself recruited from Samsung. Ramsey is looking to hire "dozens more," from the tech sector according to a GSK spokesperson.
"The pharma industry has been lagging when it comes to tech," said GSK's Ramsey in an interview with CNBC.
Ramsey sees ample opportunities for tech workers to build machine learning tools that analyze health information. One example of that is an ongoing project, depending on a green-light from the U.S. Food and Drug Administration, to use previously-collected clinical trial data as an alternative to a control arm in a study.
That could potentially reduce the cost of clinical trials, and provide a better experience for patients.
Another big area is clinical trial recruitment: Researchers are finding that it's easier, cheaper and reliable enough to find candidates via mobile technologies, versus the alternatives, which involve broad targeting with radio or paper-based ads.
"Digital devices are interesting to us, as they can capture really granular data," he said. "Typically a patient has to go to a clinic and get lab tests, which happens on an infrequent basis."
The big challenge for pharma is to build awareness in the tech community. Ramsey says it's part of his job to educate talented engineers and product managers about "all the cool things that are happening in pharma," and not to be intimidated if they don't have a health background.
Now, he said, about 80 percent of his team has no life sciences experience at all.
J&J's global health of health technology Marc Leibowitz, who previously worked at Google and Dropbox, is also building out a team in San Francisco, New York and other tech hubs.
According to LinkedIn, some of his most senior colleagues include Oliver Hsiang, a former vice president at Lyft who previously worked at Google and LinkedIn, and Jill Applebaum, also formerly of Google.